The work by Beauvais and colleagues shows that synstatin, a peptide derived from syndecan-1 active core protein, has antiangiogenic properties in vivo and in vitro, in addition to decreasing mammary carcinoma formation in nude mice. This evidence concerns the gene SDC1 and breast carcinoma.